Researchers at academic medical centers are starting to test ketamine combined with other drugs—like lithium, rapamycin, or compounds that boost BDNF (brain-derived neurotrophic factor), a protein that helps neurons grow. This approach makes scientific sense: ketamine works fast but doesn't always stick; adding something else might make the effect last longer or work better. Academic hospitals have ethics boards (IRBs) that approve these studies, and the National Institutes of Health (NIH) is funding this kind of research.
Intranasal dex-esketamine cognition combination studies already signal academic appetite. Published BDNF neuroplasticity window data provides mechanistic rationale that IRBs will accept. Ketamine clinic sector consolidation is pushing academic centers to differentiate via combination protocols. NIH HEAL Initiative funding cycles favor novel mechanism combinations. Resolves on ClinicalTrials.gov registration records with Phase 2 designation and named academic site PI.